The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

• Register: ClinicalTrials.gov
• Last refreshed on: 19 February 2015
• Main ID: NCT00097344
• Date of registration: 22/11/2004
• Prospective Registration: Yes
• Primary sponsor: Intarcia Therapeutics
• Public title: The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
• Scientific title: Phase 3 Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
• Date of first enrolment: December 2004
• Target sample size: 842
• Recruitment status: Terminated
• URL: http://clinicaltrials.gov/show/NCT00097344
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
• Phase: Phase 3

Countries of recruitment

Bulgaria, Romania, Russian Federation, Ukraine, United States

Contacts

• Name: Edith Perez, MD
• Affiliation: Professor of Medicine, Mayo Clinic, Jacksonville, Florida

Key inclusion & exclusion criteria

Inclusion Criteria:

- Women age 18 years or older

- Postmenopausal women who are to receive their first hormonal treatment for locally
recurrent, locally advanced, or metastatic disease, and who would be appropriate
candidates for treatment with antiestrogens or aromatase inhibitors.

- Locally recurrent, locally advanced, locally metastatic disease not amenable to
radiation therapy or surgery and/or distant metastatic disease.

- Pathological or histological confirmation at primary diagnosis of breast cancer or at
the time of diagnosis of advanced disease.

- ECOG performance status of 0, 1 or 2 or Karnofsky performance status of 60 or higher.

- Predicted life expectancy of 12 weeks or more.

- Postmenopausal endocrine status. LH/FSH levels in the postmenopausal range in women
whose menopause occurred less than 5 years ago.

- At least one tumor localization measurable in 2 dimensions.

- One diameter either at least 2 cm or at least two times the CT/MRI
slice/reconstruction thickness for bone/soft tissue/visceral disease assessed by
CT/MRI scan (to include spiral CT technique).

- One diameter at least 2 cm for lesions other than bone lesions assessed by
conventional X-ray techniques.

- One diameter at least 1 cm for bone lesions assessed by conventional X-ray
techniques.

- Estrogen receptor and/or progesterone receptor positive (by laboratory/institutional
standard) at the time of primary diagnosis or determined during subsequent
biopsy/surgery of metastases.

- Administration of bisphosphonates in patients with bone metastases is allowed, as
long as the drug is started prior to randomization of the patient.

- Written informed consent obtained.

Exclusion Criteria:

- Prior hormonal therapy (including oophorectomy or treatment with LH/RH analogs) to
treat locally recurrent, locally advanced, or metastatic disease.

- Prior chemotherapy to treat locally recurrent, locally advanced, or metastatic
disease.

- Prior adjuvant therapy with aromatase inhibitors or antiestrogens/SERMs with last
dose administered within 3 months prior to enrollment.

- Primary diagnosis of disease or progression of disease during therapy with
antiestrogens (including SERMs administered for prevention of osteoporosis).

- Life-threatening disease requiring chemotherapeutic intervention.

- History of known CNS metastases, significant neurological dysfunction including
active seizures, or clinical signs of other significant neurological diseases.

- Other active malignancy (except basal cell carcinoma of the skin, contralateral
breast cancer, or in situ cervical cancer). Patients with previous malignancies must
be without evidence of disease for at least five years.

- Renal insufficiency (serum creatinine >2.0 mg/dL).

- Aspartate aminotransferase, alanine aminotransferase, or serum bilirubin levels more
than 2.5 times upper limit of normal.

- Hemoglobin <9 g/dL.

- Platelet count of less than 100,000 platelets per mm3.

- Total white blood cell count of less than 2,000 cells per mm3.

- Premenopausal endocrine status; pregnant or lactating females.

- Usage of an investigational drug within thirty (30) days prior to enrollment; or the
planned usage of an investigational drug other than the study medication during the
course of the current study.

- Contraindication to use of toremifene, atamestane, letrozole, or any of the inactive
components of their formulations as stated in the investigators brochure or product
package insert.

- Patients who are unable to comply with the study requirements or diagnostic
procedures.

- Prior enrollment in this study.



Age minimum: 18 Years
Age maximum: N/A
Gender: Female

Health Condition(s) or Problem(s) studied

Breast Neoplasms

Neoplasms, Hormone-Dependent

Intervention(s)

Drug: Letrozole

Drug: Estrogen receptor blocker

Drug: Toremifene

Drug: Atamestane

Procedure: Antiestrogen therapy

Procedure: Endocrine therapy

Drug: Aromatase inhibition

Procedure: Hormone therapy

Primary Outcome(s)

Time to progression

Secondary Outcome(s)

Overall survival

Response rate

Safety

Secondary ID(s)

Biomed 777-CLP-30

Source(s) of Monetary Support

Please refer to primary and secondary sponsors